首页> 美国卫生研究院文献>Journal of Clinical and Experimental Hepatology >Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System
【2h】

Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System

机译:印度国家肝脏和印度放射成像协会肝细胞癌诊断和成像肝脏成像报告和数据系统的联合共识声明

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Hepatocellular carcinoma (HCC) is the 6th most common cancer and the second most common cause of cancer-related mortality worldwide. There are currently no universally accepted practice guidelines for the diagnosis of HCC on imaging owing to the regional differences in epidemiology, target population, diagnostic imaging modalities, and staging and transplant eligibility. Currently available regional and national guidelines include those from the American Association for the Study of Liver Disease (AASLD), the European Association for the Study of the Liver (EASL), the Asian Pacific Association for the Study of the Liver, the Japan Society of Hepatology, the Korean Liver Cancer Study Group, Hong Kong, and the National Comprehensive Cancer Network in the United States. India with its large population and a diverse health infrastructure faces challenges unique to its population in diagnosing HCC. Recently, American Association have introduced a Liver Imaging Reporting and Data System (LIRADS, version 2017, 2018) as an attempt to standardize the acquisition, interpretation, and reporting of liver lesions on imaging and hence improve the coherence between radiologists and clinicians and provide guidance for the management of HCC. The aim of the present consensus was to find a common ground in reporting and interpreting liver lesions pertaining to HCC on imaging keeping LIRADSv2018 in mind.
机译:肝细胞癌(HCC)是第6个最常见的癌症和全球癌症相关死亡率的第二个最常见的原因。由于流行病学,目标人口,诊断成像模态和分期和移植资格的区域差异,目前没有普遍接受的诊断HCC对成像的诊断。目前可用的区域和国家指南包括来自美国肝病(AASLD)研究协会,欧洲肝脏(EASL)研究协会,亚洲太平洋肝脏研究协会,日本社会肝脏学,韩国肝癌研究组,香港和美国国家综合癌症网络。印度人口较大,卫生基础设施多元化面临着诊断HCC人口独有的挑战。最近,美国协会引入了肝脏成像报告和数据系统(Lirads,2017,2018),以试图规范肝脏病变对成像的收购,解释和报告,从而提高放射科医生和临床医生之间的一致性并提供指导用于管理HCC。本共识的目的是在报告和解释与HCC有关的肝脏病变时,找到一个共同的立场,以便在留着Liradsv2018记住。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号